*  Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. - Semantic...
In previous work we transferred a human factor IX-encoding adeno-associated viral vector (AAV) into skeletal muscle of men with severe hemophilia B. Biopsy of injected muscle up to 1 year after vector injection showed evidence of gene transfer by Southern blot and of protein expression by IHC and immunofluorescent staining. Although the procedure appeared safe, circulating F.IX levels remained subtherapeutic (| 1%). Recently, we obtained muscle tissue from a subject injected 10 years earlier who died of causes unrelated to gene transfer. Using Western blot, IHC, and immunofluorescent staining, we show persistent factor IX expression in injected muscle tissue. F.IX transcripts were detected in injected skeletal muscle using RT-PCR, and isolated whole genomic DNA tested positive for the presence of the transferred AAV vector sequence. This is the longest reported transgene expression to date from a ...
  https://www.semanticscholar.org/paper/Factor-IX-expression-in-skeletal-muscle-of-a-sever-Buchlis-Podsakoff/e3aa07b9e467618ed3042df27bf3b24075c60881
*  Coagulation Factor IX (Recombinant) - DrugBank
Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ...
  https://www.drugbank.ca/drugs/DB00100
*  Healthcare Research Report: Global Human Coagulation Factor IX Market Research Report 2017 - Top Key Players including CSL, BPL...
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators ...
  http://healthcare-research-report.blogspot.com/2017/07/global-human-coagulation-factor-ix.html
*  Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for...
GAITHERSBURG, Md., April 30, 2015-- Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration has approved IXINITY ®, an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children,≥ 12 years of age, with Hemophilia B....
  https://www.cnbc.com/2015/04/30/globe-newswire-emergent-biosolutions-expands-commercial-product-portfolio-with-fda-approval-of-ixinity-a-recombinant-factor-ix-treatment.html
*  Factor IX Complex - Symptoms, Treatments and Resources for Factor IX Complex
Factor IX Complex - MedHelp's Factor IX Complex Center for Information, Symptoms, Resources, Treatments and Tools for Factor IX Complex. Find Factor IX Complex information, treatments for Factor IX Complex and Factor IX Complex symptoms.
  http://www.medhelp.org/tags/show/121140/Factor-IX-Complex
*  Natural Human Factor IX protein (ab62544) References
References for Abcam's Natural Human Factor IX protein (ab62544). Please let us know if you have used this product in your publication
  http://www.abcam.com/natural-human-factor-ix-protein-ab62544-references.html
*  Factor IX concentrate - St. Jude Children's Research Hospital
Learn more about Factor IX concentrate (also called BeneFix®). Factor IX concentrate is a medication used to help manage bleeding disorders.
  https://www.stjude.org/treatment/patient-resources/caregiver-resources/medicines/a-z-list-of-medicines/factor-9-concentrate.html
*  Baxter Announces Recombinant Factor IX Development Program For He... ( DEERFIELD Ill. Jan. 7 /- Baxter I...)
... DEERFIELD Ill. Jan. 7 /- Baxter Internati... Extending our recombinant portfolio beyond ADVATE which is indicated...Pre-clinical work on a longer-acting version of recombinant Factor IX...,Baxter,Announces,Recombinant,Factor,IX,Development,Program,For,Hemophilia,B,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
  http://www.bio-medicine.org/medicine-technology-1/Baxter-Announces-Recombinant-Factor-IX-Development-Program-For-Hemophilia-B-1158-1/
*  Preliminary study on non-viral transfection of F9 (factor IX) gene by nucleofection in human adipose-derived mesenchymal stem...
Background. Hemophilia is a rare recessive X-linked disease characterized by a deficiency of coagulation factor VIII or factor IX. Its current treatment is merely palliative. Advanced therapies are likely to become the treatment of choice for the disease as they could provide a curative treatment. Methods. The present study looks into the use of a safe non-viral transfection method based on nucleofection to express and secrete human clotting factor IX (hFIX) where human adipose tissue derived mesenchymal stem cells were used as target cells in vitro studies and NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used to analyze factor IX expression in vivo studies. Previously, acute liver injury was induced by an injected intraperitoneal dose of 500 mg/kg body weight of acetaminophen. Results. Nucleofection showed a percentage of positive cells ranging between 30.7% and 41.9% and a ...
  https://peerj.com/articles/1907/
*  Side Effects of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] Closed State
Learn about possible side effects which may occur when taking ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein].
  https://www.alprolix.com/safety/safety.html
*  BeneFIX (Coagulation Factor IX Recombinant for Injection): Side Effects, Interactions, Warning, Dosage & Uses
Learn about BeneFIX (Coagulation Factor IX Recombinant for Injection) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
  https://www.rxlist.com/benefix-drug.htm
*  Anti-Factor IX antibody [13B9] (ab17197) | Abcam
Mouse monoclonal Factor IX antibody [13B9] validated for WB, ELISA and tested in Human. Immunogen corresponding to full length native protein (purified)
  http://www.abcam.com/factor-ix-antibody-13b9-ab17197.html
*  Anti-Factor IX antibody (ab61353) | Abcam
Sheep polyclonal Factor IX antibody validated for WB, ELISA and tested in Rat. Immunogen corresponding to full length native protein (purified)
  http://www.abcam.com/factor-ix-antibody-ab61353.html
*  Anti-Factor IX antibody [13F42-F6] (ab125149) Protocols
Abcam provides specific protocols for Anti-Factor IX antibody [13F42-F6] (ab125149) : Western blot protocols, Immunohistochemistry protocols
  http://www.abcam.com/factor-ix-antibody-13f42-f6-ab125149-protocols.html
*  ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
Learn about ALPROLIX, a therapy regimen for the treatment of hemophilia B that uses Fc Fusion to keep Factor IX circulating in your bloodstream longer
  https://www.alprolix.com/
*  RSS Content | EBSI
Clinical Trial Overview. The approval of IXINITY is based on results from a Phase I/III, open-label, uncontrolled, multi-center, global study evaluating safety, efficacy, and pharmacokinetics in previously treated adults and children 12 years of age or older with severe to moderately severe (factor IX level ,2%) Hemophilia B. The pharmacokinetic results (N=32) showed that IXINITY achieved similar pharmacokinetic behavior as nonacog alfa, another licensed recombinant coagulation factor IX product. Subjects (N=68) received IXINITY either as routine or on-demand treatment of bleeding episodes. Fifty-five (55) subjects received IXINITY for ,50 exposure days and 45 received IXINITY for , 100 exposure days. No significant reduction in steady state factor IX levels or alteration in pharmacokinetic behavior occurred over time. The ...
  http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=RssLanding&cat=news&id=2042165
*  Haematology - University of Oxford, Medical Sciences Division
Scientists working in Oxford have made major contributions to this field. Robert Gwynne Macfarlane was instrumental in identifying the clotting cascade. George Brownlee first cloned the Factor IX gene, leading to the production of recombinant Factor IX now used to treat patients with haemophilia B. Sir David Weatherall pioneered research into the inherited basis of blood disorders, particularly thalassaemia, culminating in a prestigious Lasker Award in 2010. Current research in haematology is concentrated in the MRC Molecular Haematology Unit housed in the Weatherall Institute of Molecular Medicine and the Nuffield Department of Clinical Laboratory Sciences. Areas of strength include the regulation of gene expression in haematopoiesis, understanding haematopoietic stem cells and how they are perturbed in various form of leukemia. ...
  https://www.medsci.ox.ac.uk/study/graduateschool/subject-areas/haematology
*  No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated Hemophiliacs | Annals of Internal...
Post-transfusion hepatitis is a serious and frequent complication in patients treated with clotting factor concentrates made from plasma pooled from a large number of donors. The occurrence is close to 100% in hemophiliacs who have not previously received blood or blood derivatives (first-exposure patients) (1-3). Recently, several manufacturers of concentrate have developed physical or chemical methods that remove or inactivate viruses with little or no loss of clotting factor activity. One manufacturer has added hydrophobic interaction chromatography on octanohydrazide-agarose to the regular fractionation process of a commercial concentrate of clotting factors II, VII, IX, and X (4). In-vitro studies have ...
  http://annals.org/aim/article-abstract/699849/hepatitis-after-treatment-modified-factor-ix-concentrate-previously-untreated-hemophiliacs
*  Coagulation Factor Ix Recombinant (Intravenous Route) Precautions - Mayo Clinic
It is very important that your doctor check you closely while you or your child are receiving this medicine to make sure it is working properly. Blood and urine tests will be needed to check for unwanted effects. This medicine may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you or your child have a rash, itching skin, difficulty with swallowing, dizziness, a fast heartbeat, lightheadedness or fainting, restlessness, trouble breathing, swelling in your face, hands, tongue, or throat, or chest pain after you receive the medicine. ...
  https://www.mayoclinic.org/drugs-supplements/coagulation-factor-ix-recombinant-intravenous-route/precautions/drg-20061220?p=1
*  Financial Support for BeneFIX® Coagulation Factor IX (Recombinant)
Get information about support programs, including the Pfizer Factor Savings Card and Pfizer RxPathways® to help eligible patients save money on their factor
  https://www.pfizerpro.com/product/benefix/hemophilia-b/support/financial-support
*  Financial Support for BeneFIX® Coagulation Factor IX (Recombinant)
Get information about support programs, including the Pfizer Factor Savings Card and Pfizer RxPathways® to help eligible patients save money on their factor
  https://www.pfizerpro.com/product/benefix/hemophilia-b/support/financial-support?advert=advert
*  Surgical Follow-up and Outcomes sub-cluster 53
The aim of this study was to characterize the variability of bleeding phenotype and its association with plasma factor IX coagulant activity (FIX:C) in haemophilia B carriers in a large Amish pedigree with a unifying genetic mutation, C-to-T transition at base 31008 of the factor IX gene (Xq27.1-27.2). A cross-sectional ...
  http://www.biomedsearch.com/cluster/27/Surgical-Follow-up-and-Outcomes/sub-53-p8.html
*  Gentaur Molecular :Molecular Innovations \ Anti Mouse Factor IX and IXa \ MA-MFIX-2
Gentaur molecular products has all kinds of products like :search , Molecular Innovations \ Anti Mouse Factor IX and IXa \ MA-MFIX-2 for more molecular products just contact us
  http://www.antibody-antibodies.com/product_det.php?id=244647&supplier=search&name=Anti%20Mouse%20Factor%20IX%20and%20IXa